Herbert Kuster

List of Publications by Year
in descending order

23 papers	908 citations	516710 16 h-index	677142 22 g-index
23 all docs	23 docs citations	23 times ranked	1600 citing authors

#	Article	IF	Citations
1	Determinants of HIV-1 broadly neutralizing antibody induction. Nature Medicine, 2016, 22, 1260-1267.	30.7	133
2	In Vivo and In Vitro Escape from Neutralizing Antibodies 2G12, 2F5, and 4E10. Journal of Virology, 2007, 81, 8793-8808.	3.4	85
3	Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Diversity and Tropism in 145 Patients With Primary HIV-1 Infection. Clinical Infectious Diseases, 2011, 53, 1271-1279.	5.8	84
4	Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology, 2004, 326, 113-129.	2.4	76
5	HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. Aids, 2010, 24, 1177-1183.	2.2	62
6	Residual Cell-Associated Unspliced HIV-1 Rna in Peripheral Blood of Patients on Potent Antiretroviral Therapy Represents Intracellular Transcripts. Antiviral Therapy, 2002, 7, 91-103.	1.0	62
7	HumanImmunodeficiency Virus Type 1 Fitness Is a Determining Factor in ViralRebound and Set Point in ChronicInfection. Journal of Virology, 2003, 77, 13146-13155.	3.4	54
8	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. Nature, 2018, 561, 406-410.	27.8	47
9	Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood, 2004, 104, 1784-1792.	1.4	46
10	Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. PLoS ONE, 2011, 6, e27463.	2.5	46
11	Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology, 2016, 13, 62.	2.0	45
12	Low Human Immunodeficiency Virus Envelope Diversity Correlates with Low In Vitro Replication Capacity and Predicts Spontaneous Control of Plasma Viremia after Treatment Interruptions. Journal of Virology, 2005, 79, 9026-9037.	3.4	40
13	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. Journal of Experimental Medicine, 2018, 215, 1589-1608.	8.5	29
14	Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells. Journal of Experimental Medicine, 2019, 216, 2071-2090.	8.5	22
15	Monocyte-derived macrophages exhibit distinct and more restricted HIV-1 integration site repertoire than CD4+ T cells. Scientific Reports, 2016, 6, 24157.	3.3	21
16	Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial. Clinical Infectious Diseases, 2019, 69, 1489-1497.	5.8	19
17	A Novel Acute Retroviral Syndrome Severity Score Predicts the Key Surrogate Markers for HIV-1 Disease Progression. PLoS ONE, 2014, 9, e114111.	2.5	17
18	HIV-1 integration sites in CD4+ T-cells during primary, chronic, and late presentation of HIV-1 infection. JCI Insight, 2021, 6, .	5.0	7

#	Article	IF	Citations
19	Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 61-69.	2.1	6
20	A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells. Viruses, 2021, 13, 404.	3.3	3
21	The Interplay Between Replication Capacity of HIV-1 and Surrogate Markers of Disease. Journal of Infectious Diseases, 2022, 226, 1057-1068.	4.0	2
22	Gut commensal microbes do not represent a dominant antigenic source for continuous CD4⁺ Tâ€cell activation during HIVâ€1 infection. European Journal of Immunology, 2015, 45, 3107-3113.	2.9	1
23	Detecting Selection in the HIV-1 Genome during Sexual Transmission Events. Viruses, 2022, 14, 406.	3.3	1